Association for Behavior Analysis International

The Association for Behavior Analysis International® (ABAI) is a nonprofit membership organization with the mission to contribute to the well-being of society by developing, enhancing, and supporting the growth and vitality of the science of behavior analysis through research, education, and practice.


48th Annual Convention; Boston, MA; 2022

Event Details

Previous Page


Poster Session #93
BPN Saturday Poster Session: Even-Numbered Posters
Saturday, May 28, 2022
2:00 PM–3:00 PM
Exhibit Level; Exhibit Hall A
Chair: Jared T Armshaw (UNT)
6. Oxycodone and Impulsive Choice: Effects on Sensitivity to Reinforcement Magnitude and Delay in Female/Male Rats
Area: BPN; Domain: Basic Research
JUSTIN T VAN HEUKELOM (University of North Carolina Wilmington), Isabelle R Rinkert (University of North Carolina Wilmington), Thomas Wagner (University of North Carolina Wilmington), Christine E. Hughes (University of North Carolina Wilmington), Raymond C. Pitts (University of North Carolina Wilmington)
Discussant: Jared T Armshaw
Abstract: Opioid use/abuse is associated with impulsive behavior. Given the extent of prescription opioid (e.g., oxycodone) abuse, research is needed investigating behavioral mechanisms involved in opioid effects on impulsive choice. The aim of the present study was to investigate oxycodone’s effects on choice controlled by reinforcement magnitude and by reinforcement delay, and to compare those effects across sexes. Separate groups of rats completed sessions under concurrent-chains procedures in which either magnitude (1, 3, or 9 dipper presentations of a sucrose solution with a 3-s delay) or delay (3-s, 9-s, or 27-s delay to 3 dipper presentations) was manipulated within-sessions; each reinforcer dimension (magnitude and delay) was studied separately in both females (n=6) and males (n=8). Sensitivity estimates under non-drug conditions indicated that females had higher sensitivity to magnitude (M=0.67) than males (M=0.54), but males had higher sensitivity to delay (M=0.76) than females (M=0.63). Acute administration of oxycodone doses (0.1-1.0 mg/kg) decreased sensitivity to both magnitude and delay in both females and males. Although this effect was qualitatively similar across both reinforcer dimensions and across sexes, oxycodone’s effects were most reliably predicted by sensitivity during baseline; thus, oxycodone’s effects appeared to be baseline dependent.
8. TPA023B has Chlordiazepoxide-Like Discriminative Stimulus Effects but Lacks Acute Withdrawal-Like Effects
Area: BPN; Domain: Basic Research
JEMMA E. COOK (West Virginia University Institute of Technology), Andria Nanney (University of Mississippi Medical Center), Jessica Tran (University of Mississippi Medical Center), James K. Rowlett (University of Mississippi Medical Center)
Discussant: Jared T Armshaw
Abstract: While benzodiazepines are among the most commonly prescribed psychiatric medications, their use is limited by abuse liability and dependence for which there is no currently approved treatment. One potential therapeutic candidate is TPA023B, an α2/3/5GABAA-subtype partial positive allosteric modulator. A pre-clinical evaluation of TPA023B’s potential clinical use was conducted in rats that examined TPA-023B’s ability to 1.) Substitute for the nonselective benzodiazepine, chlordiazepoxide, in a drug discrimination task, 2.) Impair motor performance in a schedule-controlled behavior task compared to the nonselective benzodiazepine, diazepam, 3.) Antagonize the response rate-impairing effects of diazepam 4.) Induce benzodiazepine withdrawal-like effects in an acute-dependence arrangement compared to the benzodiazepine antagonist flumazenil. In the drug discrimination task, TPA023B fully substituted for chlordiazepoxide. In the schedule-controlled behavior task, TPA023B did not impair food-maintained behavior maintained on a fixed-ratio schedule and antagonized the response rate-impairing effects of diazepam. In the acute-dependence arrangement, TPA-023B did not induce withdrawal-like effects (i.e., disruption of responding following diazepam treatment) while flumazenil did. These results support the potential for TPA023B to substitute for benzodiazepines while not inducing significant disruption to operant behavior nor withdrawal effects in those individuals seeking to discontinue benzodiazepine use or treatment for sedative, hypnotic, and anxiolytic use disorder.
10. Evaluating Preference Stability Across Psychotropic Medication Changes in Persons with Intellectual and Developmental Disabilities
Area: BPN; Domain: Applied Research
AUTUMN KOZLUK (Brock University), Alison Cox (Brock University)
Discussant: Jared T Armshaw
Abstract: Common treatment practices for individuals diagnosed with intellectual and developmental disabilities (IDD) who engage in severe challenging behaviour include psychopharmacological intervention, behavioural intervention, or combined approaches. Some behaviour analytic researchers have suggested that psychotropic medications may act as motivating operations, in that they can alter the effectiveness of stimuli as reinforcers or punishers (Carlson et al., 2012). Thus, an individual’s experience with environmental variables and stimuli, such as foods, toys, or activities may shift in accordance with a psychotropic medication adjustment. The current project investigates the effects of psychotropic medication adjustments on preference stability, preference displacement, and participant non-selection in two persons with an IDD. Weekly preference assessments were conducted at the same time on the same day each week across a series of naturally occurring medication changes. These data were used to inform a series of analyses (e.g., correlation, visual inspection) to the project’s research questions.



Back to Top
Modifed by Eddie Soh